Table 3 SBRT reirradiation for head and neck cancer
From: Stereotactic body radiation therapy in the re-irradiation situation – a review
Clinical trial | Voynov et al. 2006 | Heron et al. 2009 | Unger et al. 2010 | Roh et al. 2009 | Ozyigit et al. 2009 | Vargo et al. 2012 |
|---|---|---|---|---|---|---|
n | 22 | 25 | 65 | 36 | 24 | 34 |
Initial therapy dose | median BED10 97.8 Gy (70.1 – 190.3 Gy) | median, 64.7 Gy | median 67 Gy (32–120 Gy) | median, 70.2 Gy (39.6 – 134.4 Gy) | median, 70 Gy (48–70 Gy) | median 61.2 Gy (42–157 Gy). |
Interval | n/s | 13 months (range, 5–94 months) | 26 months (range, 2–318 months) | 24 months (range, 3.1–252.6) | 38 months (range, 10–242 months) | 53 months (range, 1–302 months) |
Re-irradiation dose | 5 (1 – 8) x 5 Gy (3 – 16 Gy) | 5 x 5 Gy | 5 (2–5) x 6 | 3 x 10/13 Gy | 5 x 6 Gy | median dose of 40 Gy in 5 fractions (interquartile range, 30–44 Gy) |
5 x 6.4 Gy | Gy (4–12Gy) | 5 x 5/8 Gy | ||||
5 x 7.2 Gy | ||||||
5 x 8.0 Gy | median 30 Gy (21–35 Gy) | |||||
5 x 8.8 Gy | ||||||
Target size (median) | TV 19.1 cm3 (range, 2.5 – 140.3 cm3) | TV 44.8 mm3 (range, 4.2–216.6 mm3) | Target volume 75 cm3 (range, 7–276 cm3) | GTV 22.6 cm3 (range, 0.2 to 114.9 cm3) | TV 63.4 cm3 (range 26.3–170.4 cm3) | TV 19,6ml (range, 4.5 – 103.9 ml) |
Median follow-up time | 19 months (range 11–40 months) | n/s | 16 months | 17.3 months | 24 months | 10 months (range, 0–55 months) |
Local control | 26% @ 2 years | n/s | 30% @ 2 years * | 61% @ 1 year | 82% @ 2 years | 77% @ 6 months |
52.2% @ 2 years | 59% @ 1 year | |||||
Overall survival | 22% @ 2 years | median 6 months (95% CI 5–8 months) | 12 months | 52.1% @ 1 year | cancer specific survival | 76% @ 6 months |
41% @ 2 years * | 30.9% @ 2 years | |||||
64% @ 2 years | 59% @ 1 year | |||||
Toxicity | 1/22 grade 2, | 3/25 grade 1 | 19/65 acute grade 1–3 toxicities | 13/36 grade 3 acute toxicities | 5/24 severe late side effects (grade ≥ 3) | Acute/late grade 3 toxicity was 15/6%, with no grade 4–5 toxicity |
1/22 grade 3 mucositis | 1/25 grade 2 | |||||
No grade 3–5 toxicities | 3/36 late toxicity: 1 bone necrosis, 2 soft tissue necrosis | |||||
No grade 4/5 toxicitiy | ||||||
6/65 late grade 4 toxicities: arterial bleeding, soft | ||||||
tissue necrosis, fistula formation | ||||||
1 treatment related death |